IMRX Immuneering Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1790340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.4%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.5%
ROA-31.4%
ROIC (approx.)-105.3%
Asset turnover—
Leverage & solvency
Liabilities / assets7.6%
Debt / equity0.00x
Current ratio13.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $20.72M | $14.00M | $10.65M | $9.25M | $10.87M | $10.45M | $11.47M | $14.86M |
| SG&A expense | $5.06M | $5.00M | $4.68M | $4.49M | $4.51M | $4.30M | $4.01M | $3.69M |
| Operating income | -$25.79M | -$19.00M | -$15.34M | -$13.75M | -$15.38M | -$14.76M | -$15.48M | -$18.56M |
| Net income | -$24.19M | -$17.27M | -$13.46M | -$11.58M | -$14.96M | -$14.43M | -$15.05M | -$18.05M |
| EBITDA | -$25.70M | -$18.92M | -$15.25M | -$13.68M | -$15.30M | -$14.67M | -$15.40M | -$18.47M |
| EPS (basic) | -0.37 | -0.27 | -0.21 | — | -0.38 | -0.40 | -0.42 | — |
| EPS (diluted) | -0.37 | -0.27 | -0.21 | — | -0.38 | -0.40 | -0.42 | — |
| Weighted avg. shares (diluted) | 64.71M | 64.70M | 64.66M | — | 39.67M | 35.99M | 35.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $58.23M | $41.32M | $47.32M | $128.65M | $227.56M | $26.36M | $35.87M | $36.14M |
| Short-term investments | — | — | — | — | — | — | $0 | $0 |
| Current assets | $150.71M | $157.99M | $161.41M | $176.25M | $229.10M | $27.73M | $38.21M | $39.59M |
| PP&E, net | $808,952 | $879,922 | $937,008 | $938,481 | $892,553 | $964,138 | $1.05M | $1.12M |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M |
| Intangibles | $299,197 | $306,513 | $313,830 | $321,147 | $328,463 | $335,780 | $343,097 | $350,413 |
| Total assets | $182.56M | $202.06M | $214.81M | $231.99M | $241.06M | $40.06M | $50.68M | $52.71M |
| Current liabilities | $10.79M | $8.12M | $4.97M | $10.07M | $9.55M | $7.49M | $5.11M | $7.50M |
| Total liabilities | $13.88M | $11.32M | $8.29M | $13.50M | $13.08M | $11.12M | $8.84M | $11.33M |
| Shareholders' equity | $168.68M | $190.74M | $206.52M | $218.48M | $227.98M | $28.94M | $41.84M | $41.39M |
| Cash flow statement | ||||||||
| Operating cash flow | -$16.79M | -$16.50M | -$18.43M | -$9.84M | -$11.98M | -$9.45M | -$14.08M | -$14.51M |
| Capital expenditure | $15,158 | $27,367 | $79,930 | $123,910 | $7,255 | $2,116 | $8,945 | $9,356 |
| Free cash flow | -$16.80M | -$16.53M | -$18.51M | -$9.96M | -$11.98M | -$9.45M | -$14.09M | -$14.52M |
| Investing cash flow | $33.47M | $10.48M | -$63.07M | -$88.72M | -$7,255 | -$2,116 | -$8,945 | $5.49M |
| Financing cash flow | $220,174 | $24,608 | $180,760 | -$357,523 | $213.19M | -$61,958 | $13.81M | -$40,988 |
| Depreciation & amortization | $86,127 | $84,454 | $81,402 | $75,889 | $78,841 | $84,527 | $85,261 | $86,116 |
| Stock-based compensation | $2.06M | $1.63M | $1.64M | $1.64M | $1.46M | $1.52M | $1.69M | $1.72M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.